Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have received a consensus rating of “Moderate Buy” from the ten brokerages that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $11.44.

Several research analysts have commented on the company. Craig Hallum started coverage on Maravai LifeSciences in a report on Wednesday, April 10th. They set a “buy” rating and a $15.00 target price on the stock. Robert W. Baird lifted their price objective on Maravai LifeSciences from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Thursday, May 9th. Finally, The Goldman Sachs Group decreased their target price on shares of Maravai LifeSciences from $8.00 to $7.00 and set a “neutral” rating for the company in a research report on Tuesday, July 9th.

Maravai LifeSciences Stock Performance

Maravai LifeSciences stock opened at $8.28 on Friday. The business has a 50 day moving average of $8.47 and a 200-day moving average of $7.79. The company has a market capitalization of $2.09 billion, a P/E ratio of -8.36 and a beta of 0.02. Maravai LifeSciences has a 1 year low of $4.52 and a 1 year high of $12.52. The company has a debt-to-equity ratio of 0.71, a current ratio of 11.32 and a quick ratio of 10.47.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.05). The business had revenue of $64.18 million during the quarter, compared to analyst estimates of $60.84 million. Maravai LifeSciences had a negative net margin of 47.81% and a negative return on equity of 4.28%. On average, equities research analysts predict that Maravai LifeSciences will post -0.15 earnings per share for the current year.

Insider Activity

In related news, Director Gtcr Investment Xi Llc sold 9,940,974 shares of the stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $9.81, for a total transaction of $97,520,954.94. Following the transaction, the director now directly owns 20,150,005 shares of the company’s stock, valued at $197,671,549.05. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.63% of the stock is currently owned by company insiders.

Institutional Trading of Maravai LifeSciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. 12 West Capital Management LP grew its stake in Maravai LifeSciences by 13.8% in the first quarter. 12 West Capital Management LP now owns 13,202,988 shares of the company’s stock valued at $114,470,000 after acquiring an additional 1,600,000 shares during the period. Vanguard Group Inc. increased its stake in Maravai LifeSciences by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 10,038,126 shares of the company’s stock valued at $87,031,000 after purchasing an additional 34,232 shares in the last quarter. Mackenzie Financial Corp increased its stake in Maravai LifeSciences by 4.8% during the 4th quarter. Mackenzie Financial Corp now owns 5,169,176 shares of the company’s stock valued at $33,858,000 after purchasing an additional 238,335 shares in the last quarter. Braidwell LP raised its holdings in Maravai LifeSciences by 26.8% during the fourth quarter. Braidwell LP now owns 5,040,635 shares of the company’s stock worth $33,016,000 after buying an additional 1,065,778 shares during the last quarter. Finally, Pacer Advisors Inc. lifted its stake in shares of Maravai LifeSciences by 37.8% in the fourth quarter. Pacer Advisors Inc. now owns 2,955,230 shares of the company’s stock valued at $19,357,000 after buying an additional 810,957 shares in the last quarter. 50.25% of the stock is owned by institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.